Table 3.
Published reproductive and oncologic outcomes after FST of LG-ESS.
| Study, Year [Ref] | Design | FST Patients (n) |
Age (Median, Range) |
Parity | Surgery | Adjuvant Treatment | Follow Up (Median, Range) |
Recurrence, n (%) |
Death, n (%) | Total Pregnancies (n) |
ART (n) |
Details |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gu, 2021 [26] | Case report | 1 | 28 | NU | Laparotomic myomectomy during C-section | - | 96 | 0 | 0 | 2 | 0 | Full-term C-section: 2 |
| Seong, 2020 [27] | Case report | 1 | 24 | NU | Laparoscopic myomectomy | MA 320 mg/day | 35 | 0 | 0 | 0 | - | - |
| Tunc, 2019 [11] | Retrospective | 13 (LG-ESS: 6; LMS: 7) |
31.5 (26–35) |
PS: 1, NU: 5 | Excision of mass: 5 Excision of mass + staging surgery: 1 |
MA: 2 CBDCA + PTX: 1 no: 3 |
61.5 (13–142) |
4 (66.7) |
0 | 1 | 1 | No live birth |
| Chin, 2018 [28] | Case report | 1 | 34 | NU | Laparotomic myomectomy | MA 160 mg/day followed by 80 mg/day | 84 | 100 | 0 | 0 | - | - |
| Xie, 2017 [12] | Retrospective | 17 | 28 (15–37) |
NU: 15; PS: 2 | Myomectomy (laparotomic: 5; laparoscopic: 7; hysteroscopic: 5) | MPA or MA: 9; GnRHa: 4; GnRHa + LNG-IUS: 2 | 39 (4–106) |
10 (58.8) | 0 | 5 | 1 | Full-term C-section: 4 Pre-term C-section (29 W): 1 2 Recurrences during pregnancy |
| Laurelli, 2015 [13] | Prospective | 6 | 33.5 (18–40) |
NU: 4; PS: 2 | HR: 6 | MA 160 mg/day: 5 | 43.5 (30–70) |
0 | 0 | 3 | 0 | First trimester miscarriage: 1 Full-term VB: 2 |
| Jin, 2015 [14] | Retrospective | 5 | 32 (28–37) |
NU:5 | Myomectomy (laparotomic: 1; laparoscopic: 4) | MA 4; GnRHa 1 | 33 (10–39) |
2 (40) |
0 | 3 | 1 | Full-term C-section: 3 |
| Morimoto, 2015 [29] | Case report | 1 | 25 | NU | Laparotomic resection | MPA 600 mg/die | 120 | 1 (100) |
1 (100) |
0 | - | - |
| Noventa, 2015 [30] | Case report | 1 | 34 | NU | Laparoscopic myomectomy | - | 15 | 0 | 0 | 1 | 0 | Ongoing |
| Dong, 2014 [31] | Case report | 1 | 19 | NU | Laparotomic myomectomy, resection of intestinal nodule, partial omentectomy | MA 250 mg/day | 33 | 0 | 0 | 0 | - | - |
| Bai, 2014 [15] | Retrospective | 19 | NA | NA | Myomectomy: 19 | NA | 20.5 (3–53) |
15 (78.9) |
1 (5.3) |
8 | 0 | Full-term C-section: 5 Full-term VB: 3 |
| Dong, 2014 [32] | Case report | 1 | 25 | NU | Laparotomic myomectomy | MPA 250 mg/day | 32 | 0 | 0 | 1 | 0 | Full-term C-section |
| Choi, 2014 [33] | Case report | 1 | 31 | NU | HR + PLND + photodynamic therapy | Letrozole 2.5 mg | 99 | 0 | 0 | 1 | 0 | Twin pregnancy. Preterm C-section (32 W) |
| Sánchez-Ferrer, 2013 [34] | Case report | 1 | 32 | NU | Laparotomic myomectomy | MA 80 mg/day | 60 | 1 (100) |
0 | 1 | 1 | Twin dichorionic–diamniotic pregnancy. P-prom and C-section at 32 W. Recurrence during pregnancy |
| Delaney, 2012 [35] | Case report | 1 | 16 | NU | Laparotomic myomectomy | MA | 96 | 0 | 0 | 1 | 0 | Preterm C-section (34 W) |
ART: assisted reproductive technology; CBDCA: carboplatin; C-section: caesarean section; FST: fertility-sparing treatment; GnRHa: gonadotrophin-releasing hormone agonists; HR: hysteroscopic resection; LG-ESS: low-grade endometrial stromal sarcoma; LMS: leiomyosarcoma; LNG-IUS: levonorgestrel-releasing intrauterine system; MA: megestrol acetate; MPA: medroxyprogesterone acetate; n: number; NA: not available; NU: nulliparous; PLND: pelvic lymph node dissection; P-prom: preterm premature rupture of membranes; PTX: paclitaxel; VB: vaginal birth; W: weeks.